Discovery and Clinical Translation of Ceperognastat, an O-GlcNAcase (OGA) Inhibitor, for the Treatment of Alzheimer's Disease

Overview

Journal Alzheimers Dement (N Y)

Date 2025 Jan 3

PMID 39748851

Authors

William Kielbasa

Paul Goldsmith

Kevin B Donnelly

Hugh N Nuthall

Sergey Shcherbinin

Adam S Fleisher

Jorg Hendle

Susan L DuBois

Stephen L Lowe

Feiyu Fred Zhang

Eric M Woerly

Nicolas J-F Dreyfus

David Evans

Jeremy Gilmore

Michele Mancini

Cristian C Constantinescu

Roger N Gunn

David S Russell

Emily C Collins

Miroslaw Brys

Michael L Hutton

Dustin J Mergott

Affiliations

Soon will be listed here.

Abstract

Introduction: The aggregation and spread of hyperphosphorylated, pathological tau in the human brain is hypothesized to play a key role in Alzheimer's disease (AD) as well as other neurogenerative tauopathies. O-GlcNAcylation, an important post-translational modification of tau and many other proteins, is significantly decreased in brain tissue of AD patients relative to healthy controls. Increased tau O-GlcNAcylation has been shown to reduce tau pathology in mouse in vivo tauopathy models. O-GlcNAcase (OGA) catalyzes the removal of O-GlcNAc from tau thereby driving interest in OGA inhibition as a potential therapeutic approach to reduce tau pathology and slow the progression of AD.

Methods: A multidisciplinary approach was used to identify ceperognastat (LY3372689) as a potent OGA inhibitor, including an extensive discovery effort with synthetic chemistry, structure-based drug design, and in vivo OGA enzyme occupancy studies. Preclinical studies assessed the target engagement, inhibition of OGA enzyme activity, OGA enzyme occupancy, and changes in tau O-GlcNAc. Four clinical Phase 1 studies of ceperognastat in healthy participants were performed to assess clinical safety and tolerability, pharmacokinetics (PK), and enzyme occupancy.

Results: Ceperognastat is a potent, central nervous system (CNS)-penetrant, low-dose inhibitor of OGA, which can achieve > 95% OGA enzyme occupancy in animal and human brain. Overall, ceperognastat had an acceptable safety profile in Phase 1 clinical studies with no serious adverse events reported following single and multiple dosing. The PK, enzyme occupancy, and safety profile supported Phase 2 development of ceperognastat.

Discussion: Ceperognastat is an orally available, highly potent, CNS-penetrant OGA inhibitor that achieved high (> 80%) OGA enzyme occupancy and increased brain O-GlcNAc-tau preclinically. Ceperognastat demonstrated > 95% OGA enzyme occupancy in Phase 1 trials. These occupancy data informed the dose selection for the Phase 2 clinical program.

Highlights: Ceperognastat is a highly potent, CNS-penetrant OGA inhibitor.Ceperognastat is both orally available and CNS-penetrant even when given at low doses.Ceperognastat can achieve > 95% OGA enzyme occupancy in the animal and human brain.Ceperognastat had an acceptable safety profile in Phase 1 clinical studies.

References

Liu F, Iqbal K, Grundke-Iqbal I, Hart G, Gong C . O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A. 2004; 101(29):10804-9. PMC: 490015. DOI: 10.1073/pnas.0400348101. View

Paul S, Haskali M, Liow J, Zoghbi S, Barth V, Kolodrubetz M . Evaluation of a PET Radioligand to Image -GlcNAcase in Brain and Periphery of Rhesus Monkey and Knock-Out Mouse. J Nucl Med. 2018; 60(1):129-134. PMC: 6354227. DOI: 10.2967/jnumed.118.213231. View

Cunningham V, Rabiner E, Slifstein M, Laruelle M, Gunn R . Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab. 2009; 30(1):46-50. PMC: 2949110. DOI: 10.1038/jcbfm.2009.190. View

Yuzwa S, Shan X, Macauley M, Clark T, Skorobogatko Y, Vosseller K . Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat Chem Biol. 2012; 8(4):393-9. DOI: 10.1038/nchembio.797. View

Allen B, Ingram E, Takao M, Smith M, Jakes R, Virdee K . Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci. 2002; 22(21):9340-51. PMC: 6758022. View

Buee L, Bussiere T, Delacourte A, Hof P . Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000; 33(1):95-130. DOI: 10.1016/s0165-0173(00)00019-9. View

Pratt M, Vocadlo D . Understanding and exploiting the roles of O-GlcNAc in neurodegenerative diseases. J Biol Chem. 2023; 299(12):105411. PMC: 10687168. DOI: 10.1016/j.jbc.2023.105411. View

Wang X, Li W, Marcus J, Pearson M, Song L, Smith K . MK-8719, a Novel and Selective -GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy. J Pharmacol Exp Ther. 2020; 374(2):252-263. DOI: 10.1124/jpet.120.266122. View

Hyman B, Phelps C, Beach T, Bigio E, Cairns N, Carrillo M . National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012; 8(1):1-13. PMC: 3266529. DOI: 10.1016/j.jalz.2011.10.007. View

10.

Pinho T, Correia S, Perry G, Ambrosio A, Moreira P . Diminished O-GlcNAcylation in Alzheimer's disease is strongly correlated with mitochondrial anomalies. Biochim Biophys Acta Mol Basis Dis. 2018; 1865(8):2048-2059. DOI: 10.1016/j.bbadis.2018.10.037. View

11.

Alquezar C, Arya S, Kao A . Tau Post-translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation. Front Neurol. 2021; 11:595532. PMC: 7817643. DOI: 10.3389/fneur.2020.595532. View

12.

Selnick H, Hess J, Tang C, Liu K, Schachter J, Ballard J . Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies. J Med Chem. 2019; 62(22):10062-10097. DOI: 10.1021/acs.jmedchem.9b01090. View

13.

Yuzwa S, Macauley M, Heinonen J, Shan X, Dennis R, He Y . A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat Chem Biol. 2008; 4(8):483-90. DOI: 10.1038/nchembio.96. View

14.

Bartolome-Nebreda J, Trabanco A, Velter A, Buijnsters P . O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer's disease and related tauopathies: analysis of the patent literature. Expert Opin Ther Pat. 2021; 31(12):1117-1154. DOI: 10.1080/13543776.2021.1947242. View

15.

Selkoe D . Alzheimer's disease. In the beginning. Nature. 1991; 354(6353):432-3. DOI: 10.1038/354432a0. View

16.

Mullard A . Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating. Nat Rev Drug Discov. 2020; 20(1):3-5. DOI: 10.1038/d41573-020-00217-7. View

17.

Imbimbo B, Balducci C, Ippati S, Watling M . Initial failures of anti-tau antibodies in Alzheimer's disease are reminiscent of the amyloid-β story. Neural Regen Res. 2022; 18(1):117-118. PMC: 9241406. DOI: 10.4103/1673-5374.340409. View

18.

Permanne B, Sand A, Ousson S, Neny M, Hantson J, Schubert R . O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies. ACS Chem Neurosci. 2022; 13(8):1296-1314. PMC: 9026285. DOI: 10.1021/acschemneuro.2c00057. View

19.

Selkoe D . The molecular pathology of Alzheimer's disease. Neuron. 1991; 6(4):487-98. DOI: 10.1016/0896-6273(91)90052-2. View

20.

Graham D, Gray A, Joyce J, Yu D, OMoore J, Carlson G . Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy. Neuropharmacology. 2013; 79:307-13. DOI: 10.1016/j.neuropharm.2013.11.025. View